Sign in
AYTU Stock Price, Chart, Stats & News
Aytu BioPharma, Inc.
Save
18.06M
Market cap
–
Current P/E
27.93x
Forward P/E
AYTU chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 66.00% |
Operating margin | -13.85% |
Pretax margin | -38.70% |
Net margin | -39.02% |
Effective tax rate | -1.30% |
ROA | -20.04% |
ROE | -107.16% |
D/E | 1.62x |
Interest coverage ratio | -3.21x |
AYTU valuation
P/E | – |
P/S | 0.34x |
P/B | 1.84x |
P/CF | -43.86x |
P/FCF | -30.17x |
P/OCF | -43.86x |
PEG | 0.02x |
EV multiple | -1.62x |
About
Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U. S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older.
Similar securities
Based on sector and market capitalization
Report issue